Vimarsana
Biggest News Aggregation in the World

Page 15 - Daniel Lang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Lang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Lang Today - Breaking & Trending Today

David Staples: We can't trust what Canadian green groups say if we don't know who is paying them to say it - Vimarsana News

David Staples: We can't trust what Canadian green groups say if we don't know who is paying them to say it

If they want to be seen as credible, if they want the public to believe they're fully on the up-and-up, it's best they be completely transparent about who is…

Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript - Vimarsana News

Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript

ATNX earnings call for the period ending June 30, 2021.

Source: fool.com
IP : Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform - Vimarsana News

IP : Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform

Transformative, leading allogeneic NKT cell platform technology expands Athenex's cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers, respectively Total potential consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of...

IP Group plc (via Public) / Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform - Vimarsana News

IP Group plc (via Public) / Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform

05/05/2021 | Press release | Distributed by Public on 05/05/2021 00:16 Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform Transformative, leading allogeneic NKT cell platform technology expands Athenex's cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers, respectively Total potential consideration of $185 million, comprising $70 million upfront pri...

Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin - Vimarsana News

Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin Athenex, Inc.February 18, 2021 GMT Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea. PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan, Singapore, and Malaysia Athenex’s Existing Partners Include Almirall, S.A., in the United States, Europe, ...

Source: apnews.com